Meeting
2020 Genitourinary Cancers Symposium
Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
Authors
Myuran Thana
Dalhousie University, Halifax, NS, Canada
Myuran Thana , Naveen S. Basappa , Sunita Ghosh , Christian K. Kollmannsberger , Daniel Yick Chin Heng , Jeffrey Graham , Denis Soulieres , Aaron Hansen , Aly-Khan A. Lalani , Vincent Castonguay , M. Neil Reaume , Georg A. Bjarnason , Rodney H. Breau , Frederic Pouliot , Anil Kapoor , Lori Wood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 633)
Abstract #
633
Poster Bd #
D19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless
Poster
2022 ASCO Annual Meeting
Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.
First Author: Thaïs M.L. Tong
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib vs nivolumab plus cabozantinib in patients with metastatic renal cell carcinoma: A matching adjusted indirect comparison (MAIC).
First Author: Pratik Rane
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of ONO-4578 plus nivolumab in metastatic colorectal cancer.
First Author: Akihito Kawazoe